ALZHEIMER'S IMMUNOTHERAPY IN A PRIMATE MODEL OF CEREBRAL AMYLOID ANGIOPATHY

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 该项目正在研究A-免疫对松鼠猴的影响，松鼠猴是一种随着年龄增长而发生显著血管淀粉样变性的物种。我们已经证明，老年松鼠猴对A蛋白的短期免疫是安全的，并且能够诱导显着的抗体形成，A蛋白对阿尔茨海默病的发展至关重要。免疫11周后也有局限性血管病变的病理学证据，证实松鼠猴是测试阿尔茨海默病免疫疗法安全性和有效性的良好模型。本研究已开始长期免疫，以更接近地模拟人类临床使用的免疫疗法。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This project is investigating the effects of A¿-immunization in the squirrel monkey, a species that develops significant vascular ¿-amyloidosis with age. We have shown that short-term immunization of older squirrel monkeys against the A¿ protein, which is critical to the development of Alzheimer's disease, is safe and is able to induce significant antibody formation. There is also pathological evidence of limited vasculopathy after 11 weeks of immunization, confirming that squirrel monkeys are a good model for testing the safety and efficacy of immunotherapy for Alzheimer's disease. The present study has begun long-term immunization to more closely mimic human clinical use of immunization therapy.